Cleerly LABS vs iPredict Eye Screening
AI Verdict
Choose Cleerly LABS if…
Choose Cleerly LABS if your cardiology or radiology practice requires highly detailed, AI-driven analysis of coronary CT angiography (CCTA) images to precisely quantify and characterize atherosclerosis and stenosis. This tool is ideal for personalized heart disease management, including tracking disease progression and assessing ischemia in patients needing advanced cardiovascular risk stratification.
View Cleerly LABS →Choose iPredict Eye Screening if…
Choose iPredict Eye Screening if your primary care clinic or ophthalmology practice needs a fast, easy-to-operate AI-powered solution for broad screening of multiple eye conditions like AMD, Diabetic Retinopathy, and Glaucoma. This tool is particularly well-suited for high-volume patient screenings, offering rapid results and also providing valuable risk predictions for systemic diseases such as stroke and heart attack.
View iPredict Eye Screening →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly LABS | iPredict Eye Screening |
|---|---|---|
| Pricing | Varies | Contact for pricing |
| Deployment | Cloud, On-premise | Cloud-based (Software as a Medical Device), accessible in primary care settings, clinics, hospitals, and online for telemedicine and prediction apps. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
iPredict Eye ScreeningTool B emphasizes ease of operation, a touchscreen interface, and rapid results (under 5 minutes for the test, under 60 seconds for the report), making it highly accessible for primary care settings and a broader range of users. The short 2-hour training process for operators further highlights its user-friendly design.
Clinical Value
TieBoth tools offer significant clinical value in their respective specialties. Tool A provides comprehensive, quantitative analysis of coronary plaque and stenosis, aiding in personalized heart disease management and tracking progression. Tool B offers broad, efficient screening for multiple eye diseases (AMD, DR, Glaucoma) and systemic risk prediction for stroke and heart attack, enabling early detection and intervention.
Pricing & Value
iPredict Eye ScreeningTool B appears to offer better value with an estimated cost of $10-$20 per patient screening on a SaaS model, which is a fraction of potential Medicare/commercial reimbursement. In contrast, Tool A's analysis costs significantly more at $750-$1500 per analysis, often requiring out-of-pocket payment.
Enterprise Readiness
Cleerly LABSTool A explicitly states it has a Business Associate Agreement (BAA) in place, is HIPAA compliant, and FDA cleared, which are critical for enterprise adoption in healthcare. While Tool B is HIPAA compliant and FDA cleared, it does not explicitly state that it provides a BAA to its customers, a key requirement for covered entities.
Innovation
TieBoth tools demonstrate high levels of innovation. Tool A is pioneering in its comprehensive, AI-powered characterization and quantification of coronary plaque from CCTA, aiming to redefine heart disease management. Tool B innovates by combining multi-disease retinal screening with systemic risk prediction and telemedicine integration, making it a unique solution for early detection in primary care.
Support & Docs
Cleerly LABSTool A provides more specific details regarding its support, including defined operating hours (Monday-Friday, 10 am-6 pm ET with after-hours priority) and structured resources like billing guidelines and FAQs. Tool B offers general contact information but less detail on its support structure or comprehensive documentation.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly LABS | iPredict Eye Screening |
|---|---|---|
| Tool Name | Cleerly LABS | iPredict Eye Screening |
| Company | Cleerly | iHealthScreen |
| Description | AI-powered, FDA-cleared web-based software for comprehensive analysis of coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis, aiding in personalized heart disease management. | FDA-cleared AI-powered screening tool for age-related macular degeneration (AMD) in patients aged 50 years and older, alongside screening for Diabetic Retinopathy (DR) and Glaucoma. The platform also provides risk prediction for systemic diseases like stroke and heart attack, integrating with EHR and telemedicine services. |
| Key Features | AI-powered CCTA image analysis, Comprehensive coronary plaque assessment (volume, type), Stenosis detection and quantification, Ischemia detection (with Cleerly ISCHEMIA module), 3D visualization of coronary arteries, Personalized heart disease risk assessment, Tracking disease progression over time, Integration with PACS, RIS, EHR via Cleerly Proxy | AI-Based Screening for Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), and Glaucoma, Electronic Health Record (EHR) Solutions, AI-Based Telemedicine Service, Image Analyzer for Retinal Vessel, Retinal Pathology, and OCT Inspector, Online Health Risk Prediction System for Diabetic, Stroke, and Heart Attack patients, Fast results: test completed in less than 5 minutes, report in under 60 seconds, High accuracy: approximately 95% on average (AMD sensitivity 86.86%, specificity 94.13%), Easy to operate, non-invasive, with an advanced touchscreen interface |
Videos
Demos, reviews, and walkthroughs featuring Cleerly LABS and iPredict Eye Screening.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly LABS or iPredict Eye Screening
Backers
Who funded each tool's parent company.